Articles related to HEALTHCARE ACCESS

The American Academy of Sleep Medicine just clarified where combination therapy fits for chronic insomnia. Spoiler: CBT-I still wins, but pharmacotherapy alone has a narrower role.

A 9-member Delphi panel just issued 65 implementation recommendations for anti-amyloid mAbs in private practice. Here’s what counts as practice-shaping and what’s still consensus opinion.

“When one oncologist leaves, the impact is not isolated, it’s felt across an entire community. Because in rural America, when care disappears, distance becomes the diagnosis.” — Harsha Vyas, MD, Cancer Center of Middle Georgia

“This acquisition immediately advances Biogen’s ongoing transformation… with two approved, best-in-class medicines that complement our existing portfolio.”
— Christopher Viehbacher, President and CEO, Biogen

The authors suggest that an effective, smartphone-delivered CBT program could expand access to first-line treatment for GAD—particularly in settings where traditional therapy is difficult to obtain.

“Without our participation and inclusion in clinical research, the drugs and treatments being developed might not actually help improve our quality of life or prolong it, as researchers will not have the opportunity to see how we specifically respond to these treatments.” – Audrey Davis, LPC, PM-LPC, Senior Director, Health Equity at the Cancer Support Community